Jonathan Sporn, Gilgamesh CEO

The Har­vard sci­en­tist act­ing as ATAI's trea­sure trove launch­es a new psy­che­delics firm fo­cused on drug 'ana­logues'

A for­mer Har­vard and NIH sci­en­tist is re­turn­ing to the psy­che­delics field with a new biotech af­ter sell­ing his last ef­fort to the buzzy ATAI Life Sci­ences.

Gil­gamesh Phar­ma­ceu­ti­cals com­plet­ed its $27 mil­lion Se­ries A on Thurs­day, the com­pa­ny an­nounced, with plans to use the cash to prep four pro­grams for INDs and con­tin­ue ex­pand­ing its lead­er­ship team. The biotech is led by CEO Jonathan Sporn, and it’s not his first rodeo in psy­che­delics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.